Life Sciences INDUSTRIES

Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.


Recognized as a leading life sciences practice, WilmerHale has represented life sciences clients across the United States and Europe for more than four decades. From biotechnology, pharmaceutical, diagnostic and medical device companies at all stages of growth to other institutions in the space, including venture capitalists, investment banks, universities and others, we understand the business of our life sciences clients and the changing regulatory and competitive demands they face.

Contacts

Sort By
Falber, Stuart M.

Stuart M. Falber

Co-Chair, Life Sciences Group

+1 617 526 6663 (t)

stuart.falber@wilmerhale.com

Juran, Belinda M.

Belinda M. Juran

Co-Chair, Technology Transactions and Licensing Practice Group

Co-Chair, Life Sciences Group

+1 617 526 6987 (t)

belinda.juran@wilmerhale.com

Der Marderosian, Lia

Lia Der Marderosian

Co-Chair, Corporate Practice Group

+1 617 526 6982 (t)

lia.dermarderosian@wilmerhale.com

johnson-brian.jpg

Brian A. Johnson

Vice Chair, Corporate Practice Group

Co-Chair, Capital Markets

+1 212 937 7206 (t)

brian.johnson@wilmerhale.com

Singer, Steven D.

Steven D. Singer

Chair, Transactional Department

+1 212 295 6307 (t)

steven.singer@wilmerhale.com

Capabilities

WilmerHale's Life Sciences Practice has extraordinary range, and the majority of our lawyers devote a significant portion of their practice to areas critical to life sciences clients. The firm's multi-disciplinary teams work seamlessly to handle a broad range of matters for clients, including corporate finance, licensing and strategic alliances, litigation, mergers and acquisitions, intellectual property, Food and Drug Administration (FDA), competition and other regulatory matters, and securities fraud. Our lawyers advise on venture financings, public offerings, mergers and acquisitions, and licensing agreements and collaborations; protect clients' innovations through patent prosecution and portfolio development; and defend their interests in enterprise-critical patent litigation. We also represent life sciences clients in dealings with the United States and other governments on regulatory matters, including issues before the FDA and other agencies, merger clearance and enforcement actions, and public policy and strategy. Read about some of our recent life sciences transactions.

Our Life Sciences Practice includes corporate lawyers who have helped thousands of entrepreneurs successfully launch their businesses; raise billions in financing; and take their companies to sale, the public markets and/or through drug commercialization. We have a longstanding tradition of representing emerging companies and entrepreneurs across industries, and routinely offer the strategic advice and sharp business perspectives that are critical to our clients' success. Learn about our startup practice at WilmerHaleLaunch.com.

Publications & News

View

August 14, 2017

WilmerHale Counsels Investors Abingworth Bioventures and Atlas Venture in IFM Therapeutics Acquisition by Bristol-Myers Squibb

Bristol-Myers Squibb Company and IFM Therapeutics announced that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire all of the outstanding capital stock of IFM Therapeutics, a venture-backed biotech company focused on developing therapies that modulate novel targets in the innate immune system to treat cancer, autoimmunity and inflammatory disorders.

August 7, 2017

WilmerHale Reps Tetraphase Pharmaceuticals in $65M Public Offering of Common Stock

Tetraphase Pharmaceuticals, Inc. has closed on an underwritten public offering of 10,000,000 shares of its common stock for a public offering price of $6.50 per share, with gross proceeds of $65 million.

August 4, 2017

SEC Confirms Certain ICOs Are Securities Offerings; Regulators Renew Focus on Cryptocurrencies

Participants and observers in cryptocurrency markets have long expected input from the SEC on the question of whether offerings of cryptocurrencies would be subject to the federal securities laws. On July 25, the SEC issued a Report of Investigation pursuant to Section 21(a) of the Securities Exchange Act of 1934 of its investigation of an offering of digital tokens by “The DAO,” an unincorporated virtual organization.

July 31, 2017

BTI Industry Power Rankings Feature WilmerHale’s Strong Client Relationships in Key Industries

WilmerHale registers an impressive performance in the BTI Industry Power Rankings 2017, which provides insight into the law firms that are best positioned with the largest, most prestigious clients across 18 industry segments.

July 27, 2017

WilmerHale Represents Kala Pharmaceuticals in $103.5 Million IPO

On July 25, 2017, Kala Pharmaceuticals, Inc. announced the closing of its initial public offering of 6,900,000 shares of common stock, including the underwriters' exercise in full of their option to purchase an additional 900,000 shares, at the public offering price of $15.00 per share.

July 24, 2017

WilmerHale Represents Trevi Therapeutics in Securing $50M in Series C Financing

The WilmerHale deal team counseling Trevi Therapeutics was led by Stuart Falber and included Sam Rothberg and Cara Fonseca.

July 24, 2017

WilmerHale Reps Emergent BioSolutions in $96M Acquisition of GlaxoSmithKline Anthrax Drug

Emergent BioSolutions announced it would acquire a drug for treating inhaled anthrax from pharmaceutical giant GlaxoSmithKline in an all-cash deal worth up to $96 million.

July 20, 2017

WilmerHale Earns Win at Federal Circuit on Behalf of Takeda in Hatch-Waxman Litigation

The appeals court reversed a district court finding of patent invalidity based on obviousness and remanded the case with instructions to enter judgment in favor of Takeda.

July 6, 2017

WilmerHale Represents Aileron Therapeutics in IPO

Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a novel class of therapeutics called stapled peptides for cancers and other diseases, announced the pricing of its initial public offering.

June 13, 2017

Hyalex Orthopaedics Raises $16 Million Series A Financing

WilmerHale client Hyalex Orthopaedics, a medical device company advancing new products that feature HYALEX™ technology, a synthetic polymer that mimics cartilage, announced that it has raised $16 million in Series A financing.

Recognition

  • Chambers USA: America's Leading Lawyers for Business - Named WilmerHale a top law firm for life sciences from 2007-2017 with sources saying our attorneys are "responsive, efficient and very technically sophisticated." 
  • Chambers Global - Recognized WilmerHale as a leader in life sciences from 2013-2017, and noted that sources appreciate the firm's “client service, commerciality and value for money.”
  • Chambers Europe - Recognized WilmerHale as a leader in life sciences in Germany in its 2013-2017 editions.
  • Lake Whillans - The Life Sciences Law Firm Index included WilmerHale among the top three best life sciences law firms (2016, 2017), as the top firm for startup work (2017), among the top 10 deal firms (2017), the top two patent law firms (2016) and top 10 firms for thought leadership (2016).
  • Law360 - Named WilmerHale a Technology Practice Group of the Year for 2016 and a Life Sciences Practice Group of the Year for 2013 in its annual rankings, which recognize firms per practice area that have played a key role in the significant matters that made headlines and changed the legal landscape within the past year.
  • LMG Life Sciences - Ranked the firm in its 2012-2016 editions in the areas of patent prosecution, patent strategy and management, general patent litigation, Hatch-Waxman patent litigation, corporate, licensing and collaboration, M&A, venture capital and white collar/government investigations, and named WilmerHale a "Lifecycle Firm." In 2013, WilmerHale was named the winner of the "Canadian Impact Deals of the Year" award, in recognition of its representation of Enobia Pharma in its acquisition by Alexion Pharmaceuticals, Inc.
  • Managing IP - Recognized WilmerHale as one of the best in the United States for life sciences from 2013-2016. In 2013, 2016 and 2017, WilmerHale was named the "Patent Contentious Firm of the Year" and in 2013, the "Pharmaceutical IP Litigation Firm of the Year."
  • The American Lawyer - Placed WilmerHale on its 2016 "A-List" as one of the United States' leading law firms, marking the 13th year the firm received that recognition.
  • The American Lawyer - Named WilmerHale the 2014 IP Litigation Department of the Year and a finalist for its 2016 IP Litigation Department of the Year. The firm has been named a winner twice and a finalist six times since the contests launch in 2004.
  • The BTI Consulting Group Inc. - Named WilmerHale among the top 10 law firms for having strong and lasting client relationships with the pharma industry in its BTI Power Rankings 2016 report.
  • The Legal 500 US - Ranked WilmerHale among the top law firms for life sciences from 2013-2017 with sources saying the firm "brings a great deal of experience to any situation" and "has access to additional expertise/resources to help solve any problem."
  • The National Law Journal - Named WilmerHale to its 2012-2015 Intellectual Property Hot List, which honors firms that demonstrate creative strategies for litigation, patent prosecution, licensing and other transactional work.
  • U.S. News - Best Lawyers® - Recognized the firm in its 2014-2017 "Best Law Firms" lists in the first tier nationally for biotechnology law, corporate law, intellectual property litigation, patent law, securities and venture capital law. In 2017, WilmerHale received first-tier metropolitan rankings in Boston intellectual property litigation, patent law, technology law and venture capital law; in Colorado for intellectual property litigation; in New York for biotechnology law and corporate law; in San Jose for patent litigation; and in Washington DC for intellectual property litigation.